The future of cancer immunotherapy: Advances in checkpoint inhibitors and chimeric antigen receptor-T cells discussing recent progress in immunotherapy for cancer, focusing on checkpoint inhibitors and chimeric antigen receptor-T cell therapies

Authors

  • Ashwani K. Dhingra
  • Rupa Devi
  • Seema Pegowal
  • Ankita Rajput
  • Varinder Kaur
  • Jasmeen Kaur
  • Monika Verma

Keywords:

Cancer immunotherapy, chimeric antigen receptor-T cell therapy, checkpoint inhibitors, immune response, personalized treatment

Abstract

Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating the development of innovative therapeutic strategies beyond traditional treatments. Recent advances in cancer immunotherapy, particularly checkpoint inhibitors and chimeric antigen receptor T (CAR-T) cell therapy, have revolutionized the landscape of oncological care. These therapies leverage the body’s immune system to effectively target and eliminate malignant cells, demonstrating substantial efficacy in various malignancies, including melanoma, lung cancer, and hematologic cancers. This review comprehensively examines the mechanisms of immune response in cancer, detailing the functioning of checkpoint inhibitors and CAR-T cell therapies, along with their Food and Drug Administrationapproved variants and associated clinical outcomes. Moreover, we address ongoing challenges such as immune-related adverse events and manufacturing complexities, while highlighting emerging research and future directions that promise to enhance therapeutic efficacy and broaden patient access. By providing a detailed exploration of the current landscape and future possibilities in cancer immunotherapy, this review aims to contribute to the advancement of personalized and effective treatment strategies for cancer patients globally.

Author Biography

Ashwani K. Dhingra

Author Details:

Dr. Ashwani K. Dhingra,

Global Research Institute of Pharmacy,

Yamuna Nagar - 135 133, Haryana, India.

E-mail: [email protected]

Published

2024-12-09

How to Cite

Ashwani K. Dhingra, et al. “The Future of Cancer Immunotherapy: Advances in Checkpoint Inhibitors and Chimeric Antigen Receptor-T Cells Discussing Recent Progress in Immunotherapy for Cancer, Focusing on Checkpoint Inhibitors and Chimeric Antigen Receptor-T Cell Therapies”. Innovations in Pharmacy Planet, vol. 12, no. 4, Dec. 2024, pp. 69-72, https://innovationaljournals.com/index.php/ip/article/view/918.

Issue

Section

Review